| Item Type | Name |
|
Concept
|
Uric Acid
|
|
Concept
|
Urate Oxidase
|
|
Academic Article
|
We can make gout management more successful now.
|
|
Academic Article
|
Update on emerging urate-lowering therapies.
|
|
Academic Article
|
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
|
|
Academic Article
|
Clinical aspects of monosodium urate monohydrate crystal deposition disease (gout).
|
|
Academic Article
|
Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman.
|
|
Academic Article
|
Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
|
|
Academic Article
|
Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics.
|
|
Academic Article
|
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
|
|
Academic Article
|
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
|
|
Academic Article
|
Tophaceous gout: quantitative evaluation by direct physical measurement.
|
|
Academic Article
|
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
|
|
Academic Article
|
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
|
|
Academic Article
|
What do I need to know about gout?
|
|
Academic Article
|
Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?
|
|
Academic Article
|
Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
|
|
Academic Article
|
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
|
|
Academic Article
|
Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
|
|
Academic Article
|
Crystal-induced arthropathies: recent investigative advances.
|
|
Academic Article
|
Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
|
|
Academic Article
|
Inherited superactivity of phosphoribosylpyrophosphate synthetase: association of uric acid overproduction and sensorineural deafness.
|
|
Academic Article
|
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
|
|
Academic Article
|
Urate transporters: transforming the face of hyperuricemia and gout.
|
|
Academic Article
|
Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
|
|
Academic Article
|
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
|
|
Academic Article
|
Long-term management of gout: nonpharmacologic and pharmacologic therapies.
|
|
Academic Article
|
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout.
|
|
Academic Article
|
Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
|
|
Academic Article
|
An open-label, 6-month study of allopurinol safety in gout: The LASSO study.
|
|
Academic Article
|
Genetic aspects of gout.
|
|
Academic Article
|
Uricosuric effects of niridazole.
|
|
Academic Article
|
Identification of distinct PRS1 mutations in two patients with X-linked phosphoribosylpyrophosphate synthetase superactivity.
|
|
Academic Article
|
Increased PP-ribose-P synthetase activity: a genetic abnormality leading to excessive purine production and gout.
|
|
Academic Article
|
Increased purine nucleotide degradation in the central nervous system (CNS) in PRPP synthetase superactivity.
|
|
Academic Article
|
Gout with purine overproduction due to increased phosphoribosylpyrophosphate synthetase activity.
|
|
Academic Article
|
Variant human phosphoribosylpyrophosphate synthetase altered in regulatory and catalytic functions.
|
|
Academic Article
|
Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
|
|
Academic Article
|
Gout with superactive phosphoribosylpyrophosphate synthetase due to increased enzyme catalytic rate.
|
|
Academic Article
|
Diagnostic evaluation of phosphoribosylpyrophosphate synthetase activities in hemolysates.
|
|
Academic Article
|
Purine overproduction in man associated with increased phosphoribosylpyrophosphate synthetase activity.
|
|
Academic Article
|
Evaluation of the role of 5-phosphoribosyl-alpha-1-pyrophosphate synthetase in congenital hyperuricemia and gout: a simple isotopic assay and an activity stain for the enzyme.
|
|
Academic Article
|
Patterns of phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in fibroblasts from patients with gout and purine overproduction.
|
|
Academic Article
|
Fibroblast phosphoribosylpyrophosphate and ribose-5-phosphate concentration and generation in gout with purine overproduction.
|
|
Academic Article
|
Efficacy and Safety of Febuxostat Extended and Immediate Release in Patients With Gout and Renal Impairment: A Phase III Placebo-Controlled Study.
|
|
Academic Article
|
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
|
|
Grant
|
REGULATION OF PURINE NUCLEOTIDE SYNTHESIS IN HUMANS
|